Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers
View Patent ↗This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln10I antibodies. Other aspects of the invention are a method of killing an Cln101-expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal.
1. An isolated monoclonal antibody which competes for binding to the same epitope on Cln101 as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5877 and PTA-5876, wherein Cln101 comprises SEQ ID NO:1.
2. The antibody of claim 1 which binds to mammalian Cln101 in vivo or in vitro.
3. The antibody of claim 1 which internalizes upon binding to Cln101 on a mammalian cell in vivo.
4. The antibody of claim 1 which is an antibody fragment or a chimeric, a human, or a humanized antibody.
5. The antibody of claim 4 which is produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-5877 and PTA-5876.
6. The antibody of claim 1 which is conjugated to a growth inhibitory agent or a cytotoxic agent.
7. The antibody of claim 1 which is detectably labeled.
8. The antibody of claim 7 wherein the label is selected from the group comprising radioisotope, fluorescent, enzymatic, biotin, and gold particle labels.
9. The antibody of claim 4 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5877.
10. The antibody of claim 4 which is produced by a hybridoma of American Type Culture Collection accession number PTA-5876.
11. A composition comprising the antibody of claim 1 , and a carrier.
12. The composition of claim 11 , wherein the antibody is a human or humanized antibody and the carrier is a pharmaceutical carrier.
13. A kit comprising a suitable assay for measuring Cln101 levels and a suitable assay for measuring CA125 levels, wherein the assay for Cln101 comprises an antibody of claim 1 , wherein Cln101 comprises SEQ ID NO:1.
14. A kit comprising a suitable assay for measuring Cln101 levels and a suitable assay for measuring Prostate Specific Antigen (PSA) levels wherein the assay for Cln101 comprises an antibody of claim 1 , wherein Cln101 comprises SEQ ID NO:1.
15. An isolated cell that produces the antibody of claim 4 .
16. The cell of claim 15 , wherein the cell is selected from the group consisting of hybridoma cells deposited under American Type Culture Collection accession number PTA-5877 and PTA-5876.
17. The cell of claim 15 , wherein the cell is a hybridoma cell deposited under American Type Culture Collection accession number PTA-5877.
18. The cell of claim 15 , wherein the cell is a hybridoma cell deposited under American Type Culture Collection accession number PTA-5876.